ASP Isotopes Inc. Common Stock

ASP Isotopes Inc. Common Stock

ASPI
ASP Isotopes Inc. Common StockUS flagNASDAQ Global Market
6.96
USD
+0.41
- -
577.94MMarket Cap
ASP Isotopes Inc. Common Stock
ASPI
(NASDAQ Global Market)

Recent

price

6.96

P/E

ratio

- -

div

yld

- -

ROIC.AI

2021
2022
2023
2024
2025
TTM
FRC
- -
- -
0.01
0.07
0.29
0.29
Revenue per Share
- -
-0.18
-0.49
-0.58
-2.11
-1.84
Basic EPS, GAAP
- -
-0.28
-0.23
-0.5
-0.57
-0.7
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
-0.27
-0.71
-1
-2.77
-2.52
Book Value per Share
- -
0.37
0.47
0.86
3.05
3.1
Tangible Book Value per Share
- -
27
33
56
83
94
Basic Weighted Avg Shares
- -
- -
- -
4
24
27
Sales/Revenue/Turnover
- -
- -
-3,704.63
-635.96
-239.8
-275.28
Operating Margin (%)
- -
- -
- -
- -
2
5
Depreciation Expense
- -
-5
-16
-32
-175
-174
Net Income, GAAP
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
-3,761.03
-780.26
-734.17
-644.41
Profit Margin (%)
3
1
5
59
367
238
Working Capital
1
1
1
36
202
208
LT Debt
6
10
19
51
263
299
Total Equity
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
13
14
54
LT Borrowings
100
201
205
LT Finance Leases
1
2
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
93
112
126
Market Capitalization
741
412
416

Working Capital

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
174
400
309
Cash, Cash Equivalents & STI
114
333
291
Accounts Receivable, Net
17
18
2
Inventories
1
1
1
Total Current Liabilities
28
33
70
Payables & Accruals
11
16
15
ST Debt
13
14
54
Deferred Revenue
1
1
1

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
413.8%
Free Cash Flow
- -
- -
69%
Net Income, GAAP
- -
- -
441.51%
Sales/Revenue/Turnover
- -
- -
475.51%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1
1
1
1
4
2025
1
1
5
17
24
2026
4
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.16
-0.24
-0.12
- -
-0.58
2025
-0.12
-1.03
-0.15
- -
-2.11
2026
-0.06
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
ASP Isotopes Inc. (ASPI) operates as a development-stage advanced materials company focused on developing proprietary technologies and processes to produce and enrich isotopes for nuclear medicine, green energy generation, semiconductors, quantum computing, and related industries; core offerings encompass the Aerodynamic Separation Process (ASP) and Quantum Enrichment (QE) technologies for separating isotopes such as Carbon-14 (C-14), Molybdenum-100 (Mo-100), Molybdenum-98 (Mo-98), Silicon-28 (Si-28), and Ytterbium-176 (Yb-176) used in pharmaceuticals, agrochemicals, nuclear medical imaging, and high-assay low-enriched uranium (HALEU), Lithium-6, and Chlorine-37 for advanced nuclear fuels; the company also provides nuclear medicine services through its 51% majority stake in PET Labs (Pty) Ltd., a leader in South Africa and sub-Saharan Africa. Incorporated in Delaware in September 2021 with principal executive offices in Washington, DC, ASP Isotopes maintains enrichment facilities in South Africa and conducts research and development across two main segments: Nuclear Fuels and Specialist Isotopes and Related Services, targeting healthcare, technology, and energy markets primarily in the United States, South Africa, and the United Kingdom. Recent developments include the early commissioning of a Quantum Enrichment facility for Ytterbium-176 and commencement of commercial production for enriched Carbon-14 and Silicon-28 in 2025; expansion through three new facilities and strategic partnerships, such as a Series Seed funding investment of $5 million in IsoBio, Inc. in July 2025 to advance antibody-isotope conjugates for cancer treatment with potential manufacturing via PET Labs; an announced agreement for the potential acquisition of Renergen Limited to create a global critical materials leader; acquisition of intellectual property assets and a 30 SWU facility by subsidiary Quantum Leap Energy LLC in October 2025; and a return of Executive Chairman and CEO Paul Mann from temporary leave in December 2025.

Company News

MCPAPIChat
  • ASP Isotopes Stock Surges After Silicon-28 Facility Restart

  • ASP Isotopes Implements Engineering Enhancements to Silicon-28 Enrichment Facility; Successfully Restarts First 18 Stages of Silicon-28 Enrichment Facility; Commercial Shipments of Enriched Silicon-28 Expected to Commence in Q3 2026

  • ASP Isotopes Announces HALEU Supply MOU Through Subsidiary, Shares Move Higher

  • Quantum Leap Energy Enters into Memorandum of Understanding with European Nuclear Technology Company for Advanced Nuclear Fuel Supply Collaboration

  • Quantum Leap Energy Appoints Dr. Peter Fiske to Strategic Advisory Board

  • Insider Selling: ASP Isotopes (NASDAQ:ASPI) Director Sells $60,654.82 in Stock

  • ASP Isotopes (NASDAQ:ASPI) COO Sells $117,225.00 in Stock

  • ASP Isotopes (NASDAQ:ASPI) CFO Sells $126,719.52 in Stock

  • ASP Isotopes Inc. Provides Business Update

  • ASP Isotopes to Host Business Update Conference Call on April 13, 2026, at 8:00 AM ET

  • Did ASP Isotopes Inc. Insiders Breach their Fiduciary Duties to Shareholders?

  • Grabar Law Office Investigates Claims on Behalf of Investors of ASP Isotopes Inc. (ASPI) as Class Action Survives Motion to Dismiss

  • ASP Isotopes Announces Strategic Collaboration Between Quantum Leap Energy and University of Bristol to Design Advanced Laser Research Facility

  • Why ASP Isotopes Stock Is Surging Today

  • ASP Isotopes Completes Well Drilling Required for Phase 1 of Renergen Helium Project Four Months Ahead of Schedule

  • Notice to Long-Term Shareholders of ASP Isotopes Inc. (NASDAQ: ASPI); Integer Holdings Corp. (NYSE: ITGR); Molina Healthcare, Inc. (NYSE: MOH); and Soleno Therapeutics, Inc. (NASDAQ: SLNO): Grabar Law Office Investigates Claims on Your Behalf

  • OpenAI in talks with private equity firms on potential $10B enterprise AI venture: reports

  • Helium supply shock highlights fragile global market, D3 Energy CEO says

  • Notice to Long-Term Shareholders of ASP Isotopes Inc. (NASDAQ: ASPI); Camping World Holdings, Inc. (NYSE: CWH); EOS Energy Enterprise, Inc. (NASDAQ: EOSE); and Soleno Therapeutics, Inc. (NASDAQ: SLNO): Grabar Law Office Investigates Claims on Your Behalf

  • Did ASP Isotopes Inc. Insiders Breach their Fiduciary Duties to Shareholders?